Musely
Musely runs a vertically integrated teledermatology platform. Licensed dermatology professionals review a patient's case online, and the company compounds and ships personalized prescription treatments for dark spots, rosacea, anti-aging, hair loss and menopause care. It sells directly to consumers and says it has served more than 1.3 million patients (2026). Funding: about $28M of equity (Series A and B, 2013–2014), then a $360M non-dilutive financing from General Catalyst's Customer Value Fund (announced 2026). Third-party estimates put 2025 revenue at about $220M (Latka, unverified).
Funding
Every round, secondary, debt facility or acquisition involving Musely that AI Lounge tracks, newest first.
No rounds recorded yet.
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in